M
Marc A. Pfeffer
Researcher at Brigham and Women's Hospital
Publications - 815
Citations - 143710
Marc A. Pfeffer is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Heart failure & Myocardial infarction. The author has an hindex of 166, co-authored 765 publications receiving 133043 citations. Previous affiliations of Marc A. Pfeffer include Partners HealthCare & University of Miami.
Papers
More filters
Journal ArticleDOI
Influence of ejection fraction on cause‐specific mortality in heart failure with preserved ejection fraction
Navkaranbir S. Bajaj,Brian Claggett,Eldrin F. Lewis,Akshay S. Desai,James C. Fang,Eileen O'Meara,Sanjiv J. Shah,Nancy K. Sweitzer,Jerome L. Fleg,Bertram Pitt,Jean L. Rouleau,Peter V. Finn,Marc A. Pfeffer,Scott D. Solomon +13 more
TL;DR: The influence of LVEF on cause-specific death in HF with preserved ejection fraction patients is not well described, and the age and sex-adjusted annualized incidence of components of death by left ventricular ejections fraction in TOPCAT-Americas is poorly described.
Left Ventricular Assessment in Myocardial Infarction
Adrian F. Hernandez,Eric J. Velazquez,Scott D. Solomon,Rakhi Kilaru,Rafael Diaz,George Ertl,Aldo P. Maggioni,Jean-Lucien Rouleau,Wiek H. van Gilst,Marc A. Pfeffer,Robert M. Califf +10 more
TL;DR: Using a multivariable model with a propensity analysis, the association of LV assessment with in-hospital outcomes was evaluated and the association between LV assessment and discharge medications was evaluated.
Journal ArticleDOI
Cancer in cardiovascular drug trials and vice versa: a personal perspective
TL;DR: Strong and consistent information from both pioneering epidemiologic and clinical trial data have coalesced to generate convincing rationale for the use of pharmacologic agents in individuals with hypertension to lower arterial blood pressure in order to reduce their risk for subsequent major cardiovascular events.
Journal ArticleDOI
810-1 Impact of the angiotensin-receptor blocker candesartan in preventing diabetes in patients with heart failure
Salim Yusuf,Jan Östergren,Hertzel C. Gerstein,Marc A. Pfeffer,Karl Swedberg,Christopher B. Granger,John J.V. McMurray +6 more
Journal ArticleDOI
Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial.
Sergio H.R. Ramalho,Sergio H.R. Ramalho,Brian Claggett,Nancy K. Sweitzer,James C. Fang,Sanjiv J. Shah,Inder S. Anand,Bertram Pitt,Eldrin F. Lewis,Marc A. Pfeffer,Scott D. Solomon,Amil M. Shah +11 more
TL;DR: This study investigated the influence of milder obstructive lung disease – defined as the absence of use of steroids or supplemental O2 – on cardiovascular (CV) outcomes among patients with HFpEF enrolled in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial in the Americas.